603707 健友股份
已收盘 03-24 15:00:00
资讯
新帖
简况
3月23日健友股份跌7.03%，宏利集享债券A基金重仓该股
证券之星 · 03-23 16:29
3月23日健友股份跌7.03%，宏利集享债券A基金重仓该股
每周股票复盘：健友股份（603707）“健友转债”将于4月22日到期兑付
证券之星 · 03-22 03:17
每周股票复盘：健友股份（603707）“健友转债”将于4月22日到期兑付
健友股份（603707）披露“健友转债”到期兑付暨摘牌的第二次提示性公告，3月19日股价下跌1.11%
证券之星 · 03-19
健友股份（603707）披露“健友转债”到期兑付暨摘牌的第二次提示性公告，3月19日股价下跌1.11%
健友股份（603707）披露“健友转债”到期兑付暨摘牌的第一次提示性公告，3月17日股价下跌1.29%
证券之星 · 03-17
健友股份（603707）披露“健友转债”到期兑付暨摘牌的第一次提示性公告，3月17日股价下跌1.29%
健友股份新注册《肝素钠西林瓶装盒机包装设备视觉软件V4.3.0》项目的软件著作权
证券之星 · 03-12
健友股份新注册《肝素钠西林瓶装盒机包装设备视觉软件V4.3.0》项目的软件著作权
每周股票复盘：健友股份（603707）回购进展显示已支付1,500.85万元
证券之星 · 03-08
每周股票复盘：健友股份（603707）回购进展显示已支付1,500.85万元
健友股份（603707）披露股份回购进展公告，3月2日股价下跌2.63%
证券之星 · 03-02
健友股份（603707）披露股份回购进展公告，3月2日股价下跌2.63%
每周股票复盘：健友股份（603707）子公司亚硒酸注射液获FDA批准
证券之星 · 02-08
每周股票复盘：健友股份（603707）子公司亚硒酸注射液获FDA批准
健友股份(603707.SH)子公司产品亚硒酸注射液获得美国FDA批准
智通财经 · 02-04
健友股份(603707.SH)子公司产品亚硒酸注射液获得美国FDA批准
健友股份（603707）披露股份回购进展公告，2月2日股价下跌2.01%
证券之星 · 02-02
健友股份（603707）披露股份回购进展公告，2月2日股价下跌2.01%
每周股票复盘：健友股份（603707）拟转回存货跌价准备1.37亿至2.05亿元
证券之星 · 02-01
每周股票复盘：健友股份（603707）拟转回存货跌价准备1.37亿至2.05亿元
健友股份（603707）披露拟转回存货跌价准备的提示性公告，1月28日股价下跌1.14%
证券之星 · 01-28
健友股份（603707）披露拟转回存货跌价准备的提示性公告，1月28日股价下跌1.14%
每周股票复盘：健友股份（603707）回购进展公布，已回购137.9995万股
证券之星 · 01-11
每周股票复盘：健友股份（603707）回购进展公布，已回购137.9995万股
健友股份（603707）公告不向下修正健友转债转股价格，12月12日股价下跌1.08%
证券之星 · 2025-12-12
健友股份（603707）公告不向下修正健友转债转股价格，12月12日股价下跌1.08%
健友股份最新公告：丙泊酚乳状注射液获得美国FDA批准
证券之星 · 2025-12-03
健友股份最新公告：丙泊酚乳状注射液获得美国FDA批准
健友股份（603707）披露股份回购进展，12月2日股价下跌0.51%
证券之星 · 2025-12-02
健友股份（603707）披露股份回购进展，12月2日股价下跌0.51%
健友股份(603707.SH)子公司产品注射用达巴万星获得美国FDA批准
智通财经 · 2025-11-27
健友股份(603707.SH)子公司产品注射用达巴万星获得美国FDA批准
每周股票复盘：健友股份（603707）股东户数增30.18%至3.8万户
证券之星 · 2025-11-23
每周股票复盘：健友股份（603707）股东户数增30.18%至3.8万户
健友股份(603707)10月31日股东户数3.8万户，较上期增加30.18%
证券之星 · 2025-11-20
健友股份(603707)10月31日股东户数3.8万户，较上期增加30.18%
每周股票复盘：健友股份（603707）两款药品获FDA新增产线批准
证券之星 · 2025-11-16
每周股票复盘：健友股份（603707）两款药品获FDA新增产线批准
加载更多
公司概况
公司名称：
南京健友生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-07-19
主营业务：
南京健友生化制药股份有限公司的主营业务是药品原料、制剂的研发、生产和销售。公司的主要产品是标准肝素制剂、低分子肝素制剂。
发行价格：
7.21
{"stockData":{"symbol":"603707","market":"SH","secType":"STK","nameCN":"健友股份","latestPrice":9.34,"timestamp":1774335601000,"preClose":9.13,"halted":0,"volume":9300980,"delay":0,"changeRate":0.023,"floatShares":1616000000,"shares":1616000000,"eps":0.4023,"marketStatus":"已收盘","change":0.21,"latestTime":"03-24 15:00:00","open":9.3,"high":9.34,"low":9.11,"amount":85856600,"amplitude":0.0252,"askPrice":9.34,"askSize":1400,"bidPrice":9.33,"bidSize":167,"shortable":0,"etf":0,"ttmEps":0.4023,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"adjPreClose":9.13,"symbolType":"stock","openAndCloseTimeList":[[1774315800000,1774323000000],[1774328400000,1774335600000]],"highLimit":10.04,"lowLimit":8.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1615635256,"isCdr":false,"pbRate":2.25,"roa":"--","peRate":23.216505,"roe":"6.47%","epsLYR":0.51,"committee":-0.424528,"marketValue":15090000000,"turnoverRate":0.0058,"status":0,"floatMarketCap":15090000000},"requestUrl":"/m/hq/s/603707","defaultTab":"news","newsList":[{"id":"2621775216","title":"3月23日健友股份跌7.03%，宏利集享债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621775216?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:29","pubTimestamp":1774254586,"startTime":"0","endTime":"0","summary":"证券之星消息，3月23日健友股份跌7.03%，收盘报9.13元，换手率1.47%，成交量23.79万手，成交额2.22亿元。重仓健友股份的公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为宏利基金的宏利集享债券A。宏利集享债券A目前规模为1.19亿元，最新净值1.0108，较上一交易日上涨0.09%。该公募基金现任基金经理为刘晓晨。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"gpt_icon":0},{"id":"2621769799","title":"每周股票复盘：健友股份（603707）“健友转债”将于4月22日到期兑付","url":"https://stock-news.laohu8.com/highlight/detail?id=2621769799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621769799?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:17","pubTimestamp":1774120630,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，健友股份报收于9.82元，较上周的9.84元下跌0.2%。本周，健友股份3月16日盘中最高价报10.17元。2026年4月17日为最后交易日，4月20日起停止交易，4月23日起摘牌。截至2026年4月22日收市后登记在册的持有人将获得兑付。2026年4月20日至4月22日期间可转债仍可转股，当前转股价格为24.34元/股。健友股份发布“健友转债”到期兑付暨摘牌的第二次提示性公告，明确2026年4月22日为最后转股日，未转股的可转债将按面值109%赎回。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0046","BK0239"],"gpt_icon":0},{"id":"2620922180","title":"健友股份（603707）披露“健友转债”到期兑付暨摘牌的第二次提示性公告，3月19日股价下跌1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620922180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620922180?lang=zh_cn&edition=full","pubTime":"2026-03-19 22:28","pubTimestamp":1773930500,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，健友股份报收于9.83元，较前一交易日下跌1.11%，最新总市值为158.82亿元。该股当日开盘9.85元，最高9.96元，最低9.8元，成交额达9721.4万元，换手率为0.61%。近日，健友股份发布《关于“健友转债”到期兑付暨摘牌的第二次提示性公告》。公告显示，南京健友生化制药股份有限公司发行的“健友转债”将于2026年4月22日到期，兑付登记日为2026年4月22日，兑付本息金额为109.00元人民币/张（含税），兑付资金发放日为2026年4月23日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900039808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","BK0239","603707"],"gpt_icon":0},{"id":"2620473095","title":"健友股份（603707）披露“健友转债”到期兑付暨摘牌的第一次提示性公告，3月17日股价下跌1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473095","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620473095?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:31","pubTimestamp":1773757875,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，健友股份报收于9.92元，较前一交易日下跌1.29%，最新总市值为160.27亿元。该股当日开盘10.05元，最高10.12元，最低9.92元，成交额达1.12亿元，换手率为0.69%。近日，南京健友生化制药股份有限公司发布《关于“健友转债”到期兑付暨摘牌的第一次提示性公告》。公告显示，公司发行的“健友转债”将于2026年4月22日到期，兑付登记日为2026年4月22日，兑付本息金额为109.00元人民币/张（含税），兑付资金发放日为2026年4月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0239","BK0186","BK0046"],"gpt_icon":0},{"id":"2618901927","title":"健友股份新注册《肝素钠西林瓶装盒机包装设备视觉软件V4.3.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2618901927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618901927?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:52","pubTimestamp":1773251539,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健友股份（603707）新注册了《肝素钠西林瓶装盒机包装设备视觉软件V4.3.0》项目的软件著作权。今年以来健友股份新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.42亿元，同比减18.47%。通过天眼查大数据分析，南京健友生化制药股份有限公司共对外投资了11家企业，参与招投标项目332次；财产线索方面有商标信息24条，专利信息141条；此外企业还拥有行政许可163个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200001162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0046","603707"],"gpt_icon":0},{"id":"2617684146","title":"每周股票复盘：健友股份（603707）回购进展显示已支付1,500.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617684146?lang=zh_cn&edition=full","pubTime":"2026-03-08 01:55","pubTimestamp":1772906113,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：回购进展显示已支付1,500.85万元，占总股本0.09% 公司公告汇总：回购价格区间为9.56元/股至11.66元/股，未超上限 公司公告汇总南京健友生化制药股份有限公司于2025年4月28日召开董事会，审议通过回购股份议案，并经2025年5月20日股东大会审议通过。截至2026年2月28日，已累计回购137.9995万股，占总股本0.09%，支付金额1,500.85万元，成交价格区间为9.56元/股至11.66元/股。上述回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0046","603707"],"gpt_icon":0},{"id":"2616834356","title":"健友股份（603707）披露股份回购进展公告，3月2日股价下跌2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616834356?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:54","pubTimestamp":1772463258,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，健友股份报收于9.64元，较前一交易日下跌2.63%，最新总市值为155.75亿元。该股当日开盘9.83元，最高9.87元，最低9.61元，成交额达1.3亿元，换手率为0.83%。近日，健友股份发布《关于股份回购进展的公告》。公告显示，公司于2025年4月28日召开董事会，审议通过回购股份议案，并经2025年5月20日股东大会审议通过。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0186","BK0239"],"gpt_icon":0},{"id":"2609526534","title":"每周股票复盘：健友股份（603707）子公司亚硒酸注射液获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526534","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526534?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:47","pubTimestamp":1770490029,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，健友股份报收于9.77元，较上周的9.47元上涨3.17%。本周关注点来自公司公告汇总：子公司健进制药亚硒酸注射液获美国FDA批准。健友股份关于子公司产品亚硒酸注射液获得美国FDA批准的公告南京健友生化制药股份有限公司子公司健进制药有限公司收到美国食品药品监督管理局通知，其申报的亚硒酸注射液获得ANDA批准。新批准产品尚未在美国上市销售，短期内对公司业绩无重大影响，未来销售情况存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0046","BK0239"],"gpt_icon":0},{"id":"2608354974","title":"健友股份(603707.SH)子公司产品亚硒酸注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2608354974","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608354974?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:25","pubTimestamp":1770197116,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司健进制药有限公司(简称“健进制药”)于近日收到美国食品药品监督管理局(简称“美国FDA”)签发的亚硒酸注射液(600mcg/10mL)的ANDA批准通知(ANDA号：219472)。适应症：适用于需要肠外营养的成人与儿科患者，作为肠外营养液中硒的来源，用于当口服或肠内营养无法实施、不足或存在禁忌时。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健友股份(603707.SH)子公司产品亚硒酸注射液获得美国FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603707","BK0046","BK0186","BK0239"],"gpt_icon":0},{"id":"2608860956","title":"健友股份（603707）披露股份回购进展公告，2月2日股价下跌2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608860956?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:41","pubTimestamp":1770043279,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，健友股份报收于9.28元，较前一交易日下跌2.01%，最新总市值为149.93亿元。该股当日开盘9.43元，最高9.63元，最低9.25元，成交额达1.28亿元，换手率为0.84%。近日，健友股份发布《关于股份回购进展的公告》。公告显示，公司于2025年4月28日召开董事会，审议通过回购股份议案，并经2025年5月20日股东大会审议通过。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0046","603707"],"gpt_icon":0},{"id":"2608448077","title":"每周股票复盘：健友股份（603707）拟转回存货跌价准备1.37亿至2.05亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608448077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608448077?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:09","pubTimestamp":1769886551,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，健友股份报收于9.47元，较上周的9.72元下跌2.57%。本周，健友股份1月26日盘中最高价报9.79元。本周关注点公司公告汇总：健友股份拟转回存货跌价准备1.37亿至2.05亿元，预计增厚归母净利润1.16亿至1.74亿元。公司公告汇总：健友股份已完成注册资本变更登记，注册资本变更为161,563.4969万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","603707","BK0186"],"gpt_icon":0},{"id":"2606717714","title":"健友股份（603707）披露拟转回存货跌价准备的提示性公告，1月28日股价下跌1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717714?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:37","pubTimestamp":1769611033,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，健友股份报收于9.51元，较前一交易日下跌1.14%，最新总市值为153.65亿元。近日，南京健友生化制药股份有限公司发布《拟转回存货跌价准备的提示性公告》。公告显示，公司根据《企业会计准则第1号——存货》及公司会计政策，对截至2025年12月31日的存货进行初步减值测试，拟转回存货跌价准备13,700.00万元到20,500.00万元，预计导致归属于上市公司股东的净利润增加11,600.00万元到17,400.00万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800043029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"gpt_icon":0},{"id":"2602535865","title":"每周股票复盘：健友股份（603707）回购进展公布，已回购137.9995万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535865?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:26","pubTimestamp":1768069570,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，已累计回购137.9995万股，占总股本0.09%，支付金额1500.85万元，成交价格区间为9.56元/股至11.66元/股。截至2025年12月31日，累计已有726,000元“健友转债”转为公司普通股，累计转股数量为18,322股，占转股前公司总股本的0.001%。变动后公司总股本为1,615,635,256股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","BK0046","603707"],"gpt_icon":0},{"id":"2590238504","title":"健友股份（603707）公告不向下修正健友转债转股价格，12月12日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590238504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590238504?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:11","pubTimestamp":1765548669,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，健友股份报收于9.17元，较前一交易日下跌1.08%，最新总市值为148.15亿元。近日，健友股份发布关于不向下修正健友转债转股价格的公告。公告称，截至2025年12月12日，公司股票在连续三十个交易日内有十五个交易日收盘价低于当期转股价格的90%，触发“健友转债”转股价格向下修正条款。目前“健友转债”仍在转股期内，转股起止日期为2020年10月29日至2026年4月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","603707","BK0239"],"gpt_icon":0},{"id":"2588011396","title":"健友股份最新公告：丙泊酚乳状注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011396","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011396?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:58","pubTimestamp":1764752292,"startTime":"0","endTime":"0","summary":"健友股份(603707.SH)公告称，公司收到美国FDA签发的丙泊酚乳状注射液ANDA批准通知，规格包括200 mg/20 mL、500 mg/50 mL和1,000 mg/100 mL。该产品适应症为全身麻醉及镇静，参比制剂由FRESENIUS KABI USA LLC持有。公司已投入研发费用约人民币7,366.37万元。新批准产品近期将安排在美国上市销售，有望对公司经营业绩产生积极影响。但需注意销售不达预期等风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","603707","BK0186"],"gpt_icon":0},{"id":"2588105997","title":"健友股份（603707）披露股份回购进展，12月2日股价下跌0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588105997","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588105997?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:15","pubTimestamp":1764684924,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，健友股份报收于9.68元，较前一交易日下跌0.51%，最新总市值为156.39亿元。该股当日开盘9.75元，最高9.75元，最低9.65元，成交额达7122.54万元，换手率为0.46%。公司近日发布关于股份回购进展的公告，南京健友生化制药股份有限公司于2025年4月28日召开董事会，审议通过回购股份议案，并经2025年5月20日股东大会审议通过。上述回购符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0186","BK0239"],"gpt_icon":0},{"id":"2586248891","title":"健友股份(603707.SH)子公司产品注射用达巴万星获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248891","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586248891?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:20","pubTimestamp":1764231642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司健进制药有限公司(简称“健进制药”)于近日收到美国食品药品监督管理局(简称“美国FDA”)签发的注射用达巴万星，500mg/瓶的ANDA批准通知(ANDA号：218929)。该适应症：成人和儿科患者的急性细菌性皮肤和皮肤结构感染。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"健友股份(603707.SH)子公司产品注射用达巴万星获得美国FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0186","603707","BK0046","BK0239"],"gpt_icon":0},{"id":"2585103534","title":"每周股票复盘：健友股份（603707）股东户数增30.18%至3.8万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103534","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103534?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:10","pubTimestamp":1763835024,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，健友股份报收于9.84元，较上周的10.36元下跌5.02%。本周，健友股份11月17日盘中最高价报10.36元。11月21日盘中最低价报9.77元。健友股份当前最新总市值158.98亿元，在化学制药板块市值排名31/151，在两市A股市值排名1136/5167。股本股东变化股东户数变动截至2025年10月31日，健友股份股东户数为3.8万户，较9月30日增加8816.0户，增幅30.18%。户均持股数量由上期的5.53万股下降至4.25万股，户均持股市值为42.65万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"gpt_icon":0},{"id":"2584776182","title":"健友股份(603707)10月31日股东户数3.8万户，较上期增加30.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584776182","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584776182?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:43","pubTimestamp":1763631820,"startTime":"0","endTime":"0","summary":"证券之星消息，近日健友股份披露，截至2025年10月31日公司股东户数为3.8万户，较9月30日增加8816.0户，增幅为30.18%。在化学制药行业个股中，健友股份股东户数高于行业平均水平，截至10月31日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年9月30日至2025年10月31日，健友股份区间跌幅为3.09%，在此期间股东户数增加8816.0户，增幅为30.18%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000026573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","603707","BK0186","BK0239"],"gpt_icon":0},{"id":"2583512666","title":"每周股票复盘：健友股份（603707）两款药品获FDA新增产线批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512666","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583512666?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:56","pubTimestamp":1763236572,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，健友股份报收于10.36元，较上周的10.16元上涨1.97%。本周，健友股份11月14日盘中最高价报10.46元。本周关注点公司公告汇总：注射用维库溴铵新增生产场地获美国FDA批准。健友股份子公司Meitheal Pharmaceuticals, Inc.申报的醋酸奥曲肽注射液增加生产场地申请获美国FDA批准，允许在南京健友生化制药股份有限公司场地生产。新批准产品近期将安排在美国上市销售。表决程序合法有效，江苏世纪同仁律师事务所出具法律意见书确认会议合规。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774349819437,"stockEarnings":[{"period":"1week","weight":-0.0915},{"period":"1month","weight":-0.0712},{"period":"3month","weight":-0.0119},{"period":"6month","weight":-0.1459},{"period":"1year","weight":-0.3594},{"period":"ytd","weight":0.0111}],"compareEarnings":[{"period":"1week","weight":-0.0665},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.0272},{"period":"6month","weight":-0.0105},{"period":"1year","weight":0.1333},{"period":"ytd","weight":-0.0392}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京健友生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38029人(较上一季度增加30.18%)","perCapita":"42484股","listingDate":"2017-07-19","address":"江苏省南京市浦口区高新开发区MA010-1号地","registeredCapital":"161563万元","survey":" 南京健友生化制药股份有限公司的主营业务是药品原料、制剂的研发、生产和销售。公司的主要产品是标准肝素制剂、低分子肝素制剂。","listedPrice":7.21},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健友股份,603707,健友股份股票,健友股份股票老虎,健友股份股票老虎国际,健友股份行情,健友股份股票行情,健友股份股价,健友股份股市,健友股份股票价格,健友股份股票交易,健友股份股票购买,健友股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}